Peroxisome proliferator receptor (PPAR) β/δ in psoriatic patients before and after two conventional therapeutic modalities: Methotrexate and PUVA

European Journal of Dermatology

Volumn 21, Issue 5, 2011, Pages 691-695

  El Eishi, Nermine ^a   Hegazy, Rehab ^a   Abou Zeid, Ola ^a   Shaker, Olfat ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Methotrexate; Peroxisome proliferator activated receptor ; Peroxisome proliferator activated receptors; Psoriasis; PUVA; RTPCR

Indexed keywords

FOLIC ACID; MESSENGER RNA; METHOTREXATE; METHOXSALEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ADOLESCENT; ADULT; ANTIPSORIATIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PSORIASIS VULGARIS; PUVA; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; TREATMENT DURATION; ULTRAVIOLET A RADIATION;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PPAR DELTA; PPAR-BETA; PROSPECTIVE STUDIES; PSORIASIS; PUVA THERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 80054942868     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1422     Document Type: Article

References (21)

1. Kohn A, Ruland V, Patsinakidis N, Luger TA. Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol 2010; 28 (5 S 61): S138-44.
2. Sertznig P, Seifert M, Tilgen W, Reichrath J. Peroxisome proliferators-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 2008; 9: 15-31.
3. Friedmann PS, Cooper HL, Healy E. Peroxisome prolieratoractivated receptors and their relevance to dermatology. Acta Derm Venereol 2005; 85: 194-202.
4. Romanowska M, Reilly L, Palmer CN, et al. Activation of PPAR beta/delta causes a psoriasis-like skin disease in vivo. Plos One 2010; 16: 7701.
5. Villarrubia VG, Vidal-Asensi S, Pérez-Bãnasco V, et al. Lipid nutrition and the epidermal barrier: The connection between immunemediated inflammatory diseases and peroxisome proliferator-activated receptors, a new therapeutic target in psoriasis and atopic dermatitis. Actas Dermosifiliogr 2010; 101: 585-99.
6. Yacoub N, Romanowska M, Krauss S, et al. PPARδ Is a Type 1 IFN Target Gene and Inhibits apoptosis in T cells. J Invest Dermat 2008; 128: 1940-9.
7. Coven TR, Walters IB, Cardinale I, Krueger JG. PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 2009; 15: 22-7.
8. Rivier M, Safanova I, Lebruni P, et al. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998; 118: 1116-21.
9. Westergaard M, Henningsen J, Johansen C et al. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappa B in normal and lesional psoriatic skin. J Invest Dermatol 2003; 121: 110417.
10. Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-16.
11. Tan NS, Michalik L, Noy N, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001; 15: 3263-77.
12. Nijsten T, Geluyckens E, Colpaert C et al. Peroxisome proliferatoractivated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 2003; 32: 340-7.
13. Bhushan M, Young HS, Brenchley PE, Griffiths CE: Recent advances in cutaneous angiogenesis. Br J Dermatol 2002; 147: 418-425.
14. Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol 2002; 3: 159-73.
15. Erkin G, Ugur Y, Gürer CK, et al. Effect of PUVA, narrow-band UVB and cyclosporine on inflammatory cells of the psoriatic plaque. J Cutan Pathol 2007; 34: 213-9.
16. Jeffes EWB, McCullough JL, Pittelkow MR, et al. Methotrexate Therapy of Psoriasis: Differential Sensitivity of Proliferating Lymphoid and Epithelial Cells to the Cytotoxic and Growth-Inhibitory Effects of Methotrexate. J Invest Dermat 1995; 104: 183-8.
17. Rentenaar RJ, Heydendael VMR, Van Diepen FNJ, et al. Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. J Clin Immunol 2004; 24: 1573.
18. Warren RB, Griffiths, CEM. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clinics in Dermatology 2008; 26: 438-47.
19. Segal R, Dayan M, Zinger H, Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995; 101: 66-72
20. Tomoda R, Seto M, Hioki Y, et al. Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma. Clin Exp Metastasis 2005; 22: 559-64.
21. Deng H, Yan CL, Hu Y, et al. Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. Photodermatol Photoimmunol Photomed 2004; 20: 191-9.